Assessment of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in Ethiopia

Assessment of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in Ethiopia

November 12 2020
30 minutes
Webinar series
Innovations in Hepatitis Elimination
Video URL

The fourth article in the new "Innovations in Hepatitis Elimination" series is "Assessment of non-invasive markers of liver fibrosis in patients with hepatitis C in Ethiopia." This webinar will feature an interview with two of the authors of the article. The  authors will discuss the motivations and rationale behind their study to validate APRI and FIB-4 as alternatives to liver biopsy and transient elastography in the sub-Saharan African context. They will also describe potential implications of the study for revisiting WHO recommendations for APRI cutoffs for chronic hepatitis C care in sub-Saharan African countries.

Read the article here

CLD Author Interview

 

Contact globalhep [at] taskforce.org for more information

Dr. Hailemichael Desalegn
St. Paul’s Hospital Millennium Medical College, Medical Department, Addis Ababa, Ethiopia